Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Jeremy Barton, VP at Biogen Idec to Speak at Cancer Drugs Conference on January 27-28 San Diego, California - Jeremy Barton, VP of Oncology at Biogen Idec will be the keynote presenter on “Targeted Drug Delivery: How Far from the Bulls Eye?” at GTCbio’s Cancer Drugs Research & Development Conference on January 27-28, 2011 in San Diego, CA
Jeremy Barton, VP at Biogen Idec to Speak at Cancer Drugs Conference on January 27-28 San Diego, California

 

PRZOOM - /newswire/ - Monrovia, CA, United States, 2010/11/23 - Jeremy Barton, VP of Oncology at Biogen Idec will be the keynote presenter on “Targeted Drug Delivery: How Far from the Bulls Eye?” at GTCbio’s Cancer Drugs Research & Development Conference on January 27-28, 2011 in San Diego, CA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dr. Barton will address why the narrow therapeutic window of most cytotoxic drugs has limited their benefit in the clinic and normal tissue toxicity constrains the dose that can safely be administered. Linkage of a toxin to an antibody whose target may be an internalizing tumor specific antigen has the potential to achieve tumor selectivity relative to normal tissue and thereby improve the efficacy of the drug. The last 20 years have seen dramatic advances in the technologies which are used to construct such antibody drug conjugates (ADC) and there has been recent validation in the clinic of two different linkers (which bind the toxin to the antibody) and for two different toxins. This presentation will summarize the desired properties of an ADC and will show how the technological advances have contributed to the current success of such molecules. Clinical data from the two lead candidates will be presented and future advances and challenges will be discussed.

Benefits:

• An understanding of the ideal properties of an ADC;
• An introduction to ADC technology;
• A summary of the current clinical status of ADCs;
• Some thoughts for the future of these molecules in the treatment of cancer.

Dr. Barton, has 18 years experience in all phases of oncology drug development and commercialization activities in the pharmaceutical industry and has worked in Switzerland, the UK and the United States. Prior to joining Biogen Idec in July 2006, he held senior clinical research roles at Millennium, Elan, Glaxo Wellcome and Seattle Genetics as well as having his own consulting company. He currently manages the Oncology Medical Research Group at Biogen Idec. Dr. Barton is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine.

For more information visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Jeremy Barton, VP at Biogen Idec to Speak at Cancer Drugs Conference on January 27-28 San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today